Table 2.
Baseline characteristics by treatment group
| Characteristics | Group |
P value | ||||
|---|---|---|---|---|---|---|
| NT (A) | HU (B) | COMBI (C) | IFN-α2 (D) | HCs (E) | ||
| Patients, n | 19 | 37 | 23 | 23 | 42 | |
| Sex | ||||||
| Female, n (%) | 9 (47.4) | 17 (45.9) | 11 (47.8) | 8 (34.8) | 17 (40.5) | NS |
| Age, y | E vs A, P = .002∗ | |||||
| Median (range) | 62 (38-79) | 74 (53-85) | 68 (47-79) | 65 (31-81) | 71(66-74) | E vs D, P = .001; B vs A + D, P = .001; B vs C, P = .01 |
| Disease length, wk† | ||||||
| Median (range) | 207 (0-1214) | 290 (13-2124) | 76 (16-1170) | 452 (44-1183) | NA | NS |
| Treatment length, wk | ||||||
| Median (range) | NA | 210 (13-1028) | 47 (13-369) | 186 (35-587) | NA | C vs B + D, P < .01∗ |
| Body mass index, kg/m2 | ||||||
| Mean (SD) | 25.4 (4.6) | 26.3 (4.1) | 26.3 (4.1) | 26.0 (3.9) | 24.9 (2.4) | NS |
| Smoking, n (%) | ||||||
| Current smoker | 3 (15.8) | 2 (5.4) | 3 (13.0) | 0 (0) | 1(2.4) | NS |
| Former smoker | 7 (36.8) | 17 (45.9) | 9 (39.1) | 10 (34.5) | 13 (31) | |
| Never smoker | 9 (47.4) | 18 (48.6) | 11 (47.8) | 12 (52.2) | 26(61.9) | |
| Unknown | 0 (0) | 0 (0) | 0 (0) | 1 (4.3) | 2 (4.8) | |
| Hypertension, n (%) | ||||||
| Yes | 10 (52.6) | 22 (59.5) | 14 (60.9) | 9 (39.1) | 16 (38.1) | |
| No | 9 (47.4) | 15 (40.5) | 9 (39.1) | 14 (60.9) | 26 (61.9) | NS |
| Unknown | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 | |
| Comorbidity index‡ | ||||||
| Median (range) | 0 (0-9) | 1 (0-5) | 2 (0-8) | 1 (0-6) | 0 (0-4) | |
| n (%) | NS | |||||
| No comorbidities (CCI = 0) | 10 (52.6) | 11 (29.7) | 5 (21.7) | 10 (43.5) | 22 (52.4) | |
| Low burden (CCI = 1-2) | 7 (36.8) | 14 (37.8) | 13 (56.5) | 8 (34.8) | 16 (38.1) | |
| Moderate to high (CCI > 2) | 2 (10.5) | 12 (32.4) | 5 (21.7) | 5 (21.7) | 4 (9.5) | |
| Blood test | ||||||
| Leukocyte, ×109/L | ||||||
| Median (range) | 8.5 (5.2-20.0) | 6.7 (2.9-21.8) | 4.6 (2.9-7.3) | 4.1 (2.5-13.2) | 6.2 (4.5-9.4) | A vs C + D + E, P < .001∗ |
| A vs B, P = .03 | ||||||
| B vs C + D, P < .001 | ||||||
| E vs C + D, P < .001 | ||||||
| Hematocrit, % | ||||||
| Mean (SD) | 44 (4) | 42 (3) | 38 (5) | 42 (3) | 43 (3) | A vs C, P < .001§ |
| B vs C, P = .002 | ||||||
| C vs D, P = .002; C vs E, P < .001 | ||||||
| Thrombocyte, ×109/L | ||||||
| Median (range) | 415 (147-884) | 316 (120-635) | 288 (118-494) | 206 (113-820) | 227 (125-355) | A vs C, P = .03; A vs D, P < .01; A vs E, P < .001∗ |
| B vs D, P = .01; B vs E, P < .001 | ||||||
| eGFR | ||||||
| Mean (SD) | 83.8 (18.4) | 72.8 (12.2) | 75.2(15.3) | 85.1(12.2) | 73.1 (13.2) | B vs D, P = .02§ |
| JAK2 V617F allele burden‖, median (range) | 16 (0.11-49) | 8.4 (5.7-96) | 22 (0.42-59) | 6.65 (0.21-49) | 0 (0-0) | C vs D, P = .012∗ |
| E vs A + B + C + D, P < .001 | ||||||
CCI, Charlson Comorbidity Index; eGFR, estimated glomerular filtration rate; NA, not applicable; NS, not significant; SD, standard deviation.
∗
Pairwise Wilcoxon rank sum test.
†
Weeks since diagnosis of PV.
‡
Comorbidity scores were calculated using CCI.
§
Analysis of variance with post hoc Tukey honest significant difference test.
‖
JAK2 V617F allele burden at sample time.